Faron Pharmaceuticals Oy (FARN)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Faron Pharmaceuticals Oy (FARN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8014087
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:47
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:フィンランド
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Faron Pharmaceuticals Oy (Faron Pharma) is a drug company that carries out clinical stage drug discovery and development. The company’s product portfolio includes traumakine; clevegen; farbetic, an AOC3 inhibitor and D-ARDS, a diagnostic tool. Its traumakine clinical programme manages the treatment of acute respiratory distress syndrome (ARDS) an orphan lung disease. Faron’s drug platform traumakine prevents vascular leakage through the injured endothelium of several central organs. Its pipeline products concentrates on the therapeutic areas of acute organ traumas, cancer immunotherapy and vascular damage. The company also works in collaboration with academic institutions. Faron Pharma is headquartered in Turku, Finland.

Faron Pharmaceuticals Oy (FARN) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Faron Pharmaceuticals Oy, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Faron Pharmaceuticals Oy, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Faron Pharmaceuticals Oy, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Faron Pharmaceuticals Oy, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Faron Pharmaceuticals Oy, Medical Devices Deals, 2011 to YTD 2017 10
Faron Pharmaceuticals Oy, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Faron Pharmaceuticals Oy, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
Faron Pharma Enters Into Licensing Agreement With Maruishi Pharma For Traumakine 12
Faron Pharma Enters into Agreement with University of Birmingham Medical School 13
Faron Pharma Enters into Agreement with Selexis 14
Faron Pharma Enters into Joint Development Partnership with Turku PET Center 15
Licensing Agreements 16
Pharmbio Korea Enters into Licensing Agreement with Faron Pharma 16
China Medical System Enters into Licensing Agreement with Faron Pharma 17
Equity Offering 18
Faron Pharma Raises USD11.9 Million in Private Placement of Shares 18
Faron Pharma Raises USD1.3 Million in Rights Offering of Shares 19
Faron Pharma to Raise USD0.1 Million in Private Placement of Shares upon Exercise of Warrants 20
Faron Pharma Raises USD0.3 Million in Private Placement of Shares 21
Faron Pharma Raises USD6 Million in Private Placement of Shares 22
Faron Pharma Raises USD10.4 Million in Private Placement of Shares 23
Faron Pharma Raises Funds in IPO 25
Acquisition 26
A&B Acquires 15.72% Stake in Faron Pharma for USD5.6 Million 26
Faron Pharmaceuticals Oy – Key Competitors 27
Faron Pharmaceuticals Oy – Key Employees 28
Faron Pharmaceuticals Oy – Locations And Subsidiaries 29
Head Office 29
Recent Developments 30
Financial Announcements 30
Sep 06, 2017: Faron Pharmaceuticals: Interim Results for the six months ended 30 June 2017 30
Mar 29, 2017: Faron Pharmaceuticals: Final Results for the year ended 31 December 2016 32
Feb 09, 2017: Faron update for 2017 38
Sep 05, 2016: Faron Pharmaceuticals Announces Interim Results for the six months ended 30 June 2016 39
Mar 10, 2016: Faron Pharmaceuticals: Annual Results for the year ended 31 December 2015 40
Corporate Communications 41
Apr 19, 2017: Faron Pharmaceuticals: Proposed Board Changes 41
Product News 42
06/14/2016: Faron Provides Update On Clevegen at R&D Day 42
06/14/2016: Faron Provides Update on Traumakine at R&D Day 43
05/26/2016: Faron Expands R&D Strategy for Novel Immunotherapy Drug Candidate, Clevegen 44
Clinical Trials 45
Oct 24, 2016: First Traumakine Phase III patient in Japan recruited for the treatment of acute respiratory distress syndrome and Update on Pan-European Phase III Traumakine trial 45
Jan 07, 2016: Positive top-line results from the Japanese Phase II study of Traumakine for the treatment of ARDS 46
Appendix 47
Methodology 47
About GlobalData 47
Contact Us 47
Disclaimer 47

List of Tables
Faron Pharmaceuticals Oy, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Faron Pharmaceuticals Oy, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Faron Pharmaceuticals Oy, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Faron Pharmaceuticals Oy, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Faron Pharmaceuticals Oy, Deals By Therapy Area, 2011 to YTD 2017 9
Faron Pharmaceuticals Oy, Medical Devices Deals, 2011 to YTD 2017 10
Faron Pharmaceuticals Oy, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Faron Pharma Enters Into Licensing Agreement With Maruishi Pharma For Traumakine 12
Faron Pharma Enters into Agreement with University of Birmingham Medical School 13
Faron Pharma Enters into Agreement with Selexis 14
Faron Pharma Enters into Joint Development Partnership with Turku PET Center 15
Pharmbio Korea Enters into Licensing Agreement with Faron Pharma 16
China Medical System Enters into Licensing Agreement with Faron Pharma 17
Faron Pharma Raises USD11.9 Million in Private Placement of Shares 18
Faron Pharma Raises USD1.3 Million in Rights Offering of Shares 19
Faron Pharma to Raise USD0.1 Million in Private Placement of Shares upon Exercise of Warrants 20
Faron Pharma Raises USD0.3 Million in Private Placement of Shares 21
Faron Pharma Raises USD6 Million in Private Placement of Shares 22
Faron Pharma Raises USD10.4 Million in Private Placement of Shares 23
Faron Pharma Raises Funds in IPO 25
A&B Acquires 15.72% Stake in Faron Pharma for USD5.6 Million 26
Faron Pharmaceuticals Oy, Key Competitors 27
Faron Pharmaceuticals Oy, Key Employees 28

★海外企業調査レポート[Faron Pharmaceuticals Oy (FARN)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • E.ON SE:企業の発電所・SWOT分析2018
    E.ON SE - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employees (executives …
  • Dolphin Hotels plc:企業の戦略・SWOT・財務分析
    Dolphin Hotels plc - Strategy, SWOT and Corporate Finance Report Summary Dolphin Hotels plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • ABB, Ltd.:企業の戦略・SWOT・財務情報
    ABB, Ltd. - Strategy, SWOT and Corporate Finance Report Summary ABB, Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • Prudential Plc:企業のM&A・事業提携・投資動向
    Prudential Plc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Prudential Plc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestmen …
  • Orchids Paper Products Co:企業の戦略的SWOT分析
    Orchids Paper Products Co - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Prairie Farms Dairy Inc:企業の戦略・SWOT・財務情報
    Prairie Farms Dairy Inc - Strategy, SWOT and Corporate Finance Report Summary Prairie Farms Dairy Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Towngas China Co Ltd (1083):石油・ガス:M&Aディール及び事業提携情報
    Summary Towngas China Co Ltd (Towngas China), a subsidiary of The Hong Kong and China Gas Co Ltd is an oil and gas company that distributes natural gas. The company's business activities include sale and distribution of pipeline gas, gas pipe network construction, operating urban pipeline gas networ …
  • CMA CGM SA:企業のM&A・事業提携・投資動向
    CMA CGM SA - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's CMA CGM SA Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capi …
  • Kobayashi Pharmaceutical Co Ltd (4967):医療機器:M&Aディール及び事業提携情報
    Summary Kobayashi Pharmaceutical Co Ltd (Kobayashi) is a manufacturer and distributor of pharmaceutical, health and personal care products. The company offers OTC pharmaceuticals, oral hygiene products, deodorizing air fresheners, cooling gel sheets, sanitary products, household sundries, and body w …
  • Pets at Home Limited (PETS):企業の財務・戦略的SWOT分析
    Pets at Home Limited (PETS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Xcel Energy Inc:企業の戦略・SWOT・財務情報
    Xcel Energy Inc - Strategy, SWOT and Corporate Finance Report Summary Xcel Energy Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Monteloeder S.L.:戦略・SWOT・企業財務分析
    Monteloeder S.L. - Strategy, SWOT and Corporate Finance Report Summary Monteloeder S.L. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Tibet Rhodiola Pharmaceutical Holding Co Ltd (600211):企業の財務・戦略的SWOT分析
    Summary Tibet Rhodiola Pharmaceutical Holding Co Ltd (TRPHC) is a pharmaceutical company that manufactures and markets Chinese medicine. The company’s products include children shuangqing particles, little dragon capsule, nuodikang capsule, shuxioang capsules, snowy jin luohan analgesic balm, pu yu …
  • EuroSibEnergo Plc-エネルギー分野:企業M&A・提携分析
    Summary EuroSibEnergo PLC (EuroSibEnergo), a subsidiary of En+ Group is an energy company and producer of hydroelectric power. EuroSibEnergo generates, transmits and distributes electricity. It operations include extraction of coal, distribution and facilitating low cost operations. The company is e …
  • Marubeni Corporation:企業のM&A・事業提携・投資動向
    Marubeni Corporation - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Marubeni Corporation Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A …
  • Ferrellgas Partners, L.P.:企業の戦略・SWOT・財務情報
    Ferrellgas Partners, L.P. - Strategy, SWOT and Corporate Finance Report Summary Ferrellgas Partners, L.P. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • University of Pittsburgh Medical Center:企業の戦略的SWOT分析
    University of Pittsburgh Medical Center - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and m …
  • WorleyParsons Ltd (WOR):電力:M&Aディール及び事業提携情報
    Summary WorleyParsons Ltd (WorleyParsons) is a provider of professional services. Its services cover the full lifecycle, from creating new assets to sustaining and enhancing operating assets. The company provides integrated solution for deepwater developments with the associated subsea, pipelines, r …
  • Albéa Beauty Holdings S.A.:企業の戦略・SWOT・財務情報
    Albéa Beauty Holdings S.A. - Strategy, SWOT and Corporate Finance Report Summary Albéa Beauty Holdings S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Entasis Therapeutics Inc (ETTX):製薬・医療:M&Aディール及び事業提携情報
    Summary Entasis Therapeutics Inc (Entasis) is a drug development company that discovers and develops anti-infective therapies for drug-resistant bacterial infections. The company’s pipeline products include ETX2514, ETX0282, ETX0914 and Zoliflodacin. Its ETX2514 is a potent inhibitor of class A, C, …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆